|
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
| Table of Contents |
| Intro and Overview |
| Introduction |
| Business Overview |
| Trends and Forces |
| Corporate Overview (cont.) |
| Key Trends and Forces |
| Competition |
Eli Lilly and Company (NYSE: LLY) is the seventh largest pharmaceutical company with total sales of $20 billion, of which more than a quarter came from Zyprexa, a schizophrenia and bipolar disorder drug (see Antipsychotic Drug Market).[1][2] Although the patent for Zyprexa will expire in 2011, Eli Lilly has one of the youngest product portfolios in the industry -- the company has $6.64 dollars coming from new products (those launched within the last five years) for every dollar lost from patent-expiring ones, compared to an industry average of only 77 cents.[3]
Lilly's most promising pipeline products are Effient (prasugrel), a blood-thinner, and Byetta LAR, a long-acting-release version of the diabetes drug Byetta. Compared to Sanofi-Aventis and Bristol-Myers Squibb's Plavix, Effient is more effective at reducing heart attacks but also increases the risk of major bleeding, but for a net benefit.[4] Effient is under priority review by the FDA.[4] Byetta's biggest advantage over competitors is that it is just as effective but causes weight loss instead of gain, and there are indications that the long-acting version may be even more effective.[5]
2008 sales grew by 9.4 percent to $20.4 billion, and was mainly driven by a 28% growth in the depression and pain-management drug Cymbalta and 18% growth in Humalog.[2]
[edit] Corporate Overview
[edit] Major Products
Eli Lilly's top eight products have each generated net sales of more than $1 billion for 2008.[2]
- Zyprexa (23% of 2008 sales), Eli Lilly's best-selling product, is in the antipsychotic drug market for the treatment of schizophrenia, bipolar disorder, and other psychological disorders. It has also been used off-label for depression and dementia.[6] A 2005 study showed that Zyprexa was the most effective of its class, but causes significant weight gain -- 30 percent of patients gained more than 22 pounds after a year on the drug -- which leads to an increased risk for diabetes.[7][6] Since 2005, Eli Lilly has spent $1.61 billion to settle 31,200 lawsuits from patients who claimed that Zyprexa caused diabetes or other illnesses.[8] The patent for the drug expires in 2011.[9]
- Cymbalta (13% of 2008 sales) is a treatment for depression, anxiety, and pain management for diabetics. Sales of the drug grew 60% in 2007 to $2.1 billion due to expansions into new indications, making it Lilly's fastest growing and second largest product. The product's patent expires in 2013. [2]
- Humalog (8.5% of 2008 sales) is an insulin analog used for managing diabetes.
- Gemzar (8.4% of 2008 sales) is a chemotherapy drug for lung cancer, pancreatic cancer, and breast cancer. Gemzar mimics a DNA building block, preventing DNA replication and tumor growth.[10] Like many other chemotherapy drugs, this also stops the division of healthy cells, leading to severe side effects.
- Cialis (7.1% of 2008 sales) is the newest and longest-lasting erectile dysfunction drug on the market.
- Alimta (5.7% of 2008 sales) is a lung and chest cancer drug.
- Evista (5.3% of 2008 sales) is an osteoporosis drug only approved for postmenopausal women.
- Humulin (5.3% of 2008 sales) is another insulin analog used for managing diabetes.
Lilly's animal health division operates independently of its main pharmaceutical business and had sales of $1.09 billion in 2007.[2] (Read More about Eli Lilly's key trends and forces...)
[edit] References
- ↑ Fortune 500 2009: Industry: Pharmaceuticals.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 LLY 2008 10-k pg. 21
- ↑ Tough Projections for Big Pharmas: Drug Revenues Don't Look Promising.
- ↑ 4.0 4.1 Lilly's Prasugrel Is Granted FDA Priority Review.
- ↑ Wikipedia:Byetta
- ↑ 6.0 6.1 Wikipedia:Zyprexa
- ↑ Cowen and Company. Therapeutic Categories Outlook. March 2008.
- ↑ LLY 2007 10-k pg. 19
- ↑ LLY 2007 10-k pg. 13
- ↑ Wikipedia:Gemzar
| ||||||
|
|
